Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
L Cai, Y Li, J Tan, L Xu, Y Li - Journal of hematology & oncology, 2023 - Springer
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
Advances in immunotherapy for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
Next generation of immune checkpoint inhibitors and beyond
The immune system is the core defense against cancer development and progression.
Failure of the immune system to recognize and eliminate malignant cells plays an important …
Failure of the immune system to recognize and eliminate malignant cells plays an important …
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment
B Wu, X Shi, M Jiang, H Liu - Molecular Cancer, 2023 - Springer
Ongoing research has revealed that the existence of cancer stem cells (CSCs) is one of the
biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor …
biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor …
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell
immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1) …
immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1) …
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing
Head and neck squamous cell carcinoma (HNSCC) is characterized by complex relations
between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To …
between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To …
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-
tolerance and assist with immune response. In cancer, immune checkpoint pathways are …
tolerance and assist with immune response. In cancer, immune checkpoint pathways are …
NK cell-based immune checkpoint inhibition
Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an
important mode of treatment for cancer patients. The inhibition of immune checkpoints …
important mode of treatment for cancer patients. The inhibition of immune checkpoints …
CD8+ T cell exhaustion and cancer immunotherapy
Q Wang, Y Qin, B Li - Cancer letters, 2023 - Elsevier
Immunotherapy plays an increasingly important role in the treatment of most malignant
tumors, and CD8+ T cells are the most important antitumor effector cells in the process of …
tumors, and CD8+ T cells are the most important antitumor effector cells in the process of …
TIM-3: An update on immunotherapy
L Zhao, S Cheng, L Fan, B Zhang, S Xu - International …, 2021 - Elsevier
T cell immunoglobulin and mucin domain 3 (TIM-3) was originally found to be expressed on
the surface of Th1 cells, acting as a negative regulator and binding to the ligand galectin-9 to …
the surface of Th1 cells, acting as a negative regulator and binding to the ligand galectin-9 to …